Euromedis Groupe (ALEMG.PA)
EUR 4.45
(0.23%)
EUR 4.45
(0.23%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -4.43 Million EUR | -4.6% |
| 2022 | -4.48 Million EUR | -182.89% |
| 2021 | 4.38 Million EUR | -85.27% |
| 2020 | 30.99 Million EUR | 5344.71% |
| 2019 | -1.87 Million EUR | -66.58% |
| 2018 | -397.41 Thousand EUR | -119.12% |
| 2017 | 1.36 Million EUR | -33.19% |
| 2016 | 2.92 Million EUR | -40.26% |
| 2015 | 4.87 Million EUR | -10.31% |
| 2014 | 5.7 Million EUR | 19.11% |
| 2013 | 4.77 Million EUR | 36.85% |
| 2012 | 3.56 Million EUR | 250.34% |
| 2011 | 460 Thousand EUR | -69.36% |
| 2010 | 3.2 Million EUR | 348.43% |
| 2009 | -1.62 Million EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -279 Thousand EUR | 0.0% |
| 2023 Q4 | 85.9 Thousand EUR | -37.71% |
| 2023 Q3 | 137.9 Thousand EUR | 102.74% |
| 2023 Q2 | -5.03 Million EUR | -123.81% |
| 2023 Q1 | -2.25 Million EUR | 63.13% |
| 2023 FY | - EUR | -4.6% |
| 2022 FY | - EUR | -182.89% |
| 2022 Q1 | -2.54 Million EUR | 1.32% |
| 2022 Q2 | -5.35 Million EUR | -110.33% |
| 2022 Q3 | 540.5 Thousand EUR | 110.09% |
| 2022 Q4 | -6.1 Million EUR | -1229.69% |
| 2021 FY | - EUR | -85.27% |
| 2021 Q1 | 3.61 Million EUR | -85.8% |
| 2021 Q2 | 7.37 Million EUR | 103.84% |
| 2021 Q3 | -1.01 Million EUR | -113.82% |
| 2021 Q4 | -2.58 Million EUR | -153.41% |
| 2020 FY | - EUR | 5344.71% |
| 2020 Q1 | 3.73 Million EUR | 1410.53% |
| 2020 Q2 | 5.69 Million EUR | 52.5% |
| 2020 Q3 | 13.46 Million EUR | 136.46% |
| 2020 Q4 | 25.47 Million EUR | 89.11% |
| 2019 Q3 | -523.49 Thousand EUR | -40.73% |
| 2019 Q4 | -285 Thousand EUR | 45.56% |
| 2019 Q1 | -43 Thousand EUR | 0.0% |
| 2019 FY | - EUR | -66.58% |
| 2019 Q2 | -372 Thousand EUR | -765.12% |
| 2018 FY | - EUR | -119.12% |
| 2017 Q2 | -235.5 Thousand EUR | 0.0% |
| 2017 FY | - EUR | -33.19% |
| 2017 Q4 | 214.5 Thousand EUR | 0.0% |
| 2017 Q3 | 214.5 Thousand EUR | 191.08% |
| 2017 Q1 | -235.5 Thousand EUR | -125.63% |
| 2016 Q2 | 683 Thousand EUR | 0.0% |
| 2016 FY | - EUR | -40.26% |
| 2016 Q4 | 919 Thousand EUR | 0.0% |
| 2016 Q1 | 683 Thousand EUR | -14.09% |
| 2016 Q3 | 919 Thousand EUR | 34.55% |
| 2015 Q4 | 795 Thousand EUR | 0.0% |
| 2015 Q3 | 795 Thousand EUR | -7.18% |
| 2015 Q2 | 856.5 Thousand EUR | 0.0% |
| 2015 FY | - EUR | -10.31% |
| 2015 Q1 | 856.5 Thousand EUR | -20.44% |
| 2014 Q1 | 1.54 Million EUR | 22.03% |
| 2014 Q4 | 1.07 Million EUR | 0.0% |
| 2014 Q3 | 1.07 Million EUR | -30.21% |
| 2014 FY | - EUR | 19.11% |
| 2014 Q2 | 1.54 Million EUR | 0.0% |
| 2013 Q1 | 1.37 Million EUR | 37.98% |
| 2013 Q3 | 1.26 Million EUR | -8.21% |
| 2013 Q4 | 1.26 Million EUR | 0.0% |
| 2013 FY | - EUR | 36.85% |
| 2013 Q2 | 1.37 Million EUR | 0.0% |
| 2012 Q4 | 998 Thousand EUR | 0.0% |
| 2012 Q2 | 875.5 Thousand EUR | 0.0% |
| 2012 FY | - EUR | 250.34% |
| 2012 Q1 | 875.5 Thousand EUR | -2.23% |
| 2012 Q3 | 998 Thousand EUR | 13.99% |
| 2011 Q4 | 895.5 Thousand EUR | 0.0% |
| 2011 Q3 | 895.5 Thousand EUR | 0.0% |
| 2011 FY | - EUR | -69.36% |
| 2010 FY | - EUR | 348.43% |
| 2009 FY | - EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Affluent Medical SA | -13.34 Million EUR | 66.76% |
| Bluelinea Société Anonyme | -323.98 EUR | -1368869.998% |
| Carmat SA | -50.45 Million EUR | 91.209% |
| Diagnostic Medical Systems S.A. | -7.05 Million EUR | 37.152% |
| Eurobio Scientific Société anonyme | 18.98 Million EUR | 123.36% |
| Ikonisys S.A. | -2.34 Million EUR | -88.93% |
| Implanet S.A. | -5.07 Million EUR | 12.642% |
| Median Technologies SA | -19.58 Million EUR | 77.354% |
| SpineGuard SA | -3.49 Million EUR | -26.835% |
| Theraclion SA | -4.48 Million EUR | 1.16% |
| Euroapi S.A. | -155.39 Million EUR | 97.146% |
| Guerbet SA | 98.83 Million EUR | 104.487% |
| Ion Beam Applications SA | 12.53 Million EUR | 135.397% |
| Koninklijke Philips N.V. | 1.04 Billion EUR | 100.426% |
| Sequana Medical NV | -29.13 Million EUR | 84.778% |